1. A PHASE 1B/2 STUDY OF ORAL NANATINOSTAT (N) AND VALGANCICLOVIR (VG) IN SUBJECTS WITH EPSTEIN‐BARR VIRUS (EBV)‐ASSOCIATED LYMPHOMAS. (12th June 2019) Authors: Porcu, P.; Haverkos, B.; Brem, E.; Vallurupalli, A.; Feldman, T.; Alpdogan, O.; Brammer, J.; Bryan, L.J.; Barta, S.; Schriefer, A.; Obrzut, S.; Shen, H.; Rochford, R.; Baiocchi, R.; Casper, C.; Gutheil, J.; Melink, T.; Kearns, C.; Burner, D.; McRae, R. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 335 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CLINICAL OUTCOMES IN PATIENTS WITH EPSTEIN‐BARR VIRUS (EBV)‐POSITIVE NON‐B CELL LYMPHOMA AT THE OHIO STATE UNIVERSITY JAMES COMPREHENSIVE CANCER CENTER (OSU JAMES CCC). (12th June 2019) Authors: Brammer, J.E.; Shindiapina, P.; Freud, A.; Weigel, C.; Oakes, C.; Mishra, A.; Mundy‐Bosse, B.; Porcu, P.; Baiocchi, R. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 476 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CLINICAL OUTCOMES OF PATIENTS WITH T‐CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA (T‐LGLL) AT THE OHIO STATE UNIVERSITY JAMES COMPREHENSIVE CANCER CENTER (OSU JAMES‐CCC). (12th June 2019) Authors: Brammer, J.E.; Braunstein, Z.; Mishra, A.; Byrd, J.; Staub, A.; Freud, A.; Baiocchi, R.; Porcu, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 481 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Duvelisib, an oral dual PI3K‐δ, γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial. (12th June 2019) Authors: Horwitz, S.M.; Foss, F.M.; Porcu, P.; Moskowitz, A.; Mehta‐Shah, N.; Jacobsen, E.; Khodadoust, M.S.; Kim, Y.H.; Weinstock, D.; Lustgarten, S.; Baglio, M.; Youssoufian, H.; Brammer, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. EP-1629: Lung tumor tracking using CBCT-based respiratory motion models driven by external surrogates. (May 2017) Authors: Fassi, A.; Bombardieri, A.; Ivaldi, G.B.; Liotta, M.; Tabarelli de Fatis, P.; Meaglia, I.; Porcu, P.; Riboldi, M.; Baroni, G. Journal: Radiotherapy and oncology Issue: Volume 123:(2017:May)Supplement 1 Page Start: S882 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. EP-1757: Intra-fraction patient movements during SBRT: CBCT vs Surface Optical Markers. (April 2016) Authors: Tabarelli De Fatis, P.; Fassi, A.; Liotta, M.; Meaglia, I.; Porcu, P.; Bocci, C.; Baroni, G.; Ivaldi, G. Journal: Radiotherapy and oncology Issue: Volume 119(2016)Supplement 1 Page Start: S823 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Evaluation of planning target volume margins by analyzing intra-fraction patient movements during stereotactic body radiation therapy (SBRT) of lung lesions. Issue 1 (February 2016) Authors: Liotta, M.; Fassi, A.; De Fatis, P. Tabarelli; Meaglia, I.; Porcu, P.; Bocci, C.; Riboldi, M.; Baroni, G.; Ivaldi, G. Journal: Physica medica Issue: Volume 32:Issue 1(2016)supplement 1 Page Start: 35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. GEMCITABINE PLUS LIPOSOMAL DOXORUBICIN FOR RELAPSED REFRACTORY T‐CELL LYMPHOMAS. (June 2017) Authors: Waller, A.; Lundberg, J.; Porter, K.; Hwang, S.; Hastings, J.; Haverkos, B.; Brammer, J.; Fabbro, S.; William, B.M.; Dotson, E.; Porcu, P. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 396 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Intensity-modulated Radiotherapy for Rectal Cancer in the UK in 2020. Issue 4 (April 2021) Authors: Hanna, C.R.; Slevin, F.; Appelt, A.; Beavon, M.; Adams, R.; Arthur, C.; Beasley, M.; Duffton, A.; Gilbert, A.; Gollins, S.; Harrison, M.; Hawkins, M.A.; Laws, K.; O'Cathail, S.; Porcu, P.; Robinson, M.; Sebag-Montefiore, D.; Teo, M.; Teoh, S.; Muirhead, R. Journal: Clinical oncology Issue: Volume 33:Issue 4(2021) Page Start: 214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. LACUTAMAB IN PATIENTS (PTS) WITH ADVANCED MYCOSIS FUNGOIDES (MF) ACCORDING TO KIR3DL2 EXPRESSION: EARLY RESULTS FROM THE TELLOMAK PHASE 2 TRIAL. (17th June 2021) Authors: Bagot, M.; Kim, Y.; Zinzani, P. L.; Dalle, S.; Beylot‐barry, M.; Ortiz‐Romero, P. L; Cambalia, A.; Dereure, O.; Mortier, L.; Jacobsen, E.; Rotolo, F.; Azim, H. A; Porcu, P. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗